[ANTI-TNF (INFLIXIMAB) TREATMENT IN CROHN DISEASE: SAFETY PROFILE

Angelo Baldassare Cefalu', Antonio Carroccio, Lidia Di Prima, Giuseppe Ambrosiano, Lidia Di Prima, Davide Noto, Giuseppe Pirrone, Giuseppe Ambrosiano, Angelo B. Cefalù, Antonio Carroccio

Risultato della ricerca: Article

3 Citazioni (Scopus)

Abstract

Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma
Lingua originaleEnglish
pagine (da-a)108-112
Numero di pagine5
RivistaRecenti Progressi in Medicina
Volume97
Stato di pubblicazionePublished - 2006

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Entra nei temi di ricerca di '[ANTI-TNF (INFLIXIMAB) TREATMENT IN CROHN DISEASE: SAFETY PROFILE'. Insieme formano una fingerprint unica.

  • Cita questo

    Cefalu', A. B., Carroccio, A., Di Prima, L., Ambrosiano, G., Di Prima, L., Noto, D., Pirrone, G., Ambrosiano, G., Cefalù, A. B., & Carroccio, A. (2006). [ANTI-TNF (INFLIXIMAB) TREATMENT IN CROHN DISEASE: SAFETY PROFILE. Recenti Progressi in Medicina, 97, 108-112.